New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Articles|September 1, 1997
Supplements and Featured Publications
- The Treatment of Hypercholesterolemia: A Managed Care Perspective
- Volume 3
- Issue 8 Suppl
Bibliography
Advertisement
Articles in this issue
about 29 years ago
Goals and Objectivesabout 29 years ago
Introductionabout 29 years ago
The Rationale for Treating Hypercholesterolemiaabout 29 years ago
Managing Comorbidities through Cholesterol-Loweringabout 29 years ago
CME Quizabout 29 years ago
Selected Abstractsabout 29 years ago
ParticipantsAdvertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Simple operational changes are proving more effective at closing gaps in cardiovascular-kidney-metabolic (CKM) syndrome care than education campaigns alone, according to panelists at at Population Health Roundtable
Panelists at AJMC roundtables in Philadelphia, Boston, Washington, DC, and Chicago traced why atopic dermatitis stays undertreated despite new therapies.
Eye care access for underserved patients with diabetes is limited and poorly understood. We identified barriers and innovative solutions to improve overall care and establish evidence-based practices.
Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5